Shots:
The US FDA has granted BTD to investigate the use of its personalized, adjustable therapy i.e., deep brain stimulation (DBS) system for treatment-resistant depression
Abbott’s DBS system delivers electrical pulses to modify abnormal brain activity and is used to treat the symptoms of people with movement disorders i.e., Parkinson’s disease and essential tremor
The program aims to give patients and clinicians quick access to these treatments by speeding their development, evaluation, and review while preserving regulatory criteria for pre-market approval. The company is currently working with the US FDA to develop a plan for evaluating the device’s safety and effectiveness
Ref: Abbott | Image: Abbott
